Skip to content

Language Matters: Exploring the Impact of Language Concordance on Fertility Treatment Progression

Language Matters: Exploring the Impact of Language Concordance on Fertility Treatment Progression

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06636838
Acronym
ImpaLa
Enrollment
70
Registered
2024-10-15
Start date
2024-10-15
Completion date
2025-12-30
Last updated
2025-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Infertility Assisted Reproductive Technology, Infertility (IVF Patients), Ovulation Ind

Keywords

Spanish speaking, Spanish, infertility, Infertility work-up, IVF

Brief summary

Currently, patients presenting to the Fertility and Reproductive Medicine Center meet with an English-speaking provider and communicate through an interpreter, as none of the physicians speak Spanish. However, this study PI is a native Spanish speaker and certified bilingual clinician. Thus, this study is looking to evaluate whether or not the use of an interpreter delays completion of testing and initiation of fertility treatment. The medically indicated testing, procedures, and course of treatment will not be altered as a result of participation in the study. Participants will be asked to complete a survey in their preferred language to gauge satisfaction and communication efficacy. This proposed study is significant as it seeks to address a critical gap in the understanding of how language concordance between healthcare providers and patients influences treatment outcomes in fertility care. With Spanish being the most commonly spoken non-English language in the U.S., evaluating the impact of Spanish language skills in medical care is both timely and essential. This research will shed light on whether Spanish-speaking patients experience better treatment progression and outcomes when cared for by language-concordant providers versus when interpreters are used in fertility care. This prospective study will be conducted at Washington University's Fertility and Reproductive Medicine Center over a 12-month period. The investigators aim to enroll a total of 70 Spanish-speaking patients, based on previous patient trends at the Center 35 will be randomized to the intervention group (being evaluated and treated by a Spanish-speaking provider), and 35 will be randomized to standard of care (communicating with an English-speaking provider through an interpreter).

Interventions

BEHAVIORALSpanish-Speaking Provider

Spanish speaking patients will be seen by our Spanish-speaking provider

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must be greater than 18 years old * Preferred language must be Spanish speaking * Must be seeking fertility treatment

Exclusion criteria

* Preferred language English * Not currently seeking fertility care * Less than 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Completion of diagnostic tests90 days from initial consultation.The primary outcome is the time from the patients initial consultation to the completion of the recommended fertility diagnostic tests such as blood work or a pelvic ultrasound. Given that the tests are typically specific to the menstrual cycle, the investigators want know if the patients are completing their work-up faster when they see a Spanish-speaking physician thus understanding the instructions versus when the English speaking providers use an interpreter. The work-up only includes the labs and imaging that was recommended during their initial visit. The outcome will be measured by the unit - days.

Secondary

MeasureTime frameDescription
Patient satisfaction and communication90 days from initial consultation.Patient satisfaction and communication effectiveness, assessed through surveys administered after the initial consultation. The survey is a validated survey that uses a point system metric to conclude patient satisfaction similar to the PHQ-9 survey.

Countries

United States

Contacts

Primary ContactAileen Portugal, MD
aileenp@wustl.edu619-993-4298

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026